Fulcrum Therapeutics, Inc.
Narrative signal
Fulcrum Therapeutics, Inc.’s revenue growth stands at 2,752% for Dec 2024. Year-over-year, the metric shifted by +2,807.8 pts, translating into a +5,034.55% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Price-to-Earnings Ratio
-30x
Price-to-Sales Ratio
3.6x
Price-to-Book Ratio
1.2x
EV / EBITDA
-13.3x
Dividend Yield
0%
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• Fulcrum Therapeutics, Inc. trades at $8.90 with a market footprint around $481.6M.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at 2,752%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics, Inc. (FULC) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is Fulcrum Therapeutics, Inc. (FULC) stock price today?
Fulcrum Therapeutics, Inc. (FULC) trades near $8.90 as of Dec 5, 2025, 9:00 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is Fulcrum Therapeutics, Inc.'s market capitalization?
Fulcrum Therapeutics, Inc.'s equity is valued around $481.6M, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for Fulcrum Therapeutics, Inc.?
Fulcrum Therapeutics, Inc.'s 52-week range runs from $2.32 — $12.19. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in Fulcrum Therapeutics, Inc. stock?
Fulcrum Therapeutics, Inc. most recently moved about 1.7M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does Fulcrum Therapeutics, Inc. pay a dividend?
Fulcrum Therapeutics, Inc. currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is Fulcrum Therapeutics, Inc.'s intraday trading range?
Fulcrum Therapeutics, Inc. has traded between $8.63 — $9.67 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the Fulcrum Therapeutics, Inc. stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for Fulcrum Therapeutics, Inc. from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.